New drug trial offers hope for Tough-to-Treat stomach cancers
NCT ID NCT07115485
Summary
This study is testing a new drug called HLX43 in people with advanced stomach or gastroesophageal cancer that has continued to grow despite standard treatment. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors and help patients live longer. About 60 participants will receive the drug by IV infusion at different dose levels to determine the best one for further testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.